Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | CDYL2 | Q8N8U2 | 5/20 | 0.47 |
| ▸ | CDYL | Q9Y232 | 5/20 | 0.47 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | CBX7 | O95931 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20527438 | 0.86 | LMNA (0.53) | SMN1; SMN2LMNAMAPTNPC1RAB9A | |
| SCHEMBL20527528 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAMAPTKDM4EMEN1 | |
| SCHEMBL20527665 | 0.84 | KMT2A (0.53) | SMN1; SMN2LMNAMAPTNPC1RAB9A | |
| Bromide SCHEMBL3853189 | 0.84 | LMNA (0.71) | SMN1; SMN2LMNAMAPTNPC1KDM4E | |
| SCHEMBL5722008 | 0.84 | MEN1 (0.64) | SMN1; SMN2CDYL2CDYLCDY1; CDY1BMAPT | |
| SCHEMBL20527669 | 0.83 | CDYL2 (0.48) | SMN1; SMN2LMNACDYL2CDYLCDY1; CDY1B | |
| SCHEMBL20527559 | 0.83 | CDYL2 (0.46) | SMN1; SMN2CDYL2CDYLCDY1; CDY1BMAPT | |
| SCHEMBL20527467 | 0.83 | LMNA (0.68) | SMN1; SMN2LMNAMAPTNPC1KDM4E | |
| Bromide SCHEMBL6010196 | 0.82 | MEN1 (0.56) | SMN1; SMN2LMNACDYL2CDYLCDY1; CDY1B | |
| SCHEMBL20527661 | 0.82 | LMNA (0.59) | SMN1; SMN2LMNAMAPTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | ALTEON, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | CHRM2 1000/4885CHRM1 1576/4885CHRM3 1444/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | CHRM2 88/4885CHRM1 264/4885CHRM3 31/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | CHRM2 669/4885CHRM1 1237/4885CHRM3 740/4885 |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, COL2A1 | CHRM2 76/4885CHRM1 66/4885CHRM3 596/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | CHRM2 1287/4885CHRM1 2185/4885CHRM3 1335/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | CHRM2 835/4885CHRM1 1591/4885CHRM3 1311/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | CHRM2 52/4885CHRM1 69/4885CHRM3 307/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | CHRM2 552/4885CHRM1 768/4885CHRM3 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.